75 related articles for article (PubMed ID: 10810198)
1. [Contribution of positron emission tomography for the management of lung cancer].
Bury T; Rigo P
Rev Pneumol Clin; 2000 Apr; 56(2):125-31. PubMed ID: 10810198
[TBL] [Abstract][Full Text] [Related]
2. [18FDG-PET applications in thoracic oncology].
Bury T; Daenen F; Duysinx B; Bartsch P; Corhay JL
Rev Mal Respir; 2001 Dec; 18(6 Pt 1):623-30. PubMed ID: 11924183
[TBL] [Abstract][Full Text] [Related]
3. [Contribution of PET using FDG in the diagnosis of lung cancer--first results].
Rubinstein R; Breuer R; Chisin R
Harefuah; 2001 Feb; 140(2):100-3, 191. PubMed ID: 11242909
[TBL] [Abstract][Full Text] [Related]
4. Fluorodeoxyglucose-positron emission tomography in the detection and staging of lung cancer.
Sazon DA; Santiago SM; Soo Hoo GW; Khonsary A; Brown C; Mandelkern M; Blahd W; Williams AJ
Am J Respir Crit Care Med; 1996 Jan; 153(1):417-21. PubMed ID: 8542152
[TBL] [Abstract][Full Text] [Related]
5. [Positron emission tomography in the evaluation of intrathoracic lymphatic extension of non-small cell bronchial cancer. A preliminary study of 30 patients].
Bury T; Corhay JL; Paulus P; Weber T; D'Harcour JB; Limet R; Rigo P; Radermecker MF
Rev Mal Respir; 1996 Jul; 13(3):281-6. PubMed ID: 8765921
[TBL] [Abstract][Full Text] [Related]
6. Controlled prospective study of positron emission tomography using the glucose analogue [18f]fluorodeoxyglucose in the evaluation of pulmonary nodules.
Präuer HW; Weber WA; Römer W; Treumann T; Ziegler SI; Schwaiger M
Br J Surg; 1998 Nov; 85(11):1506-11. PubMed ID: 9823912
[TBL] [Abstract][Full Text] [Related]
7. [Value of Pet-18FDG in lung cancer].
Richter JA; Torre W; Gámez C; Aramendia JM; Crespo A; Nicolás A; Brugarolas A
Med Clin (Barc); 1999 Nov; 113(15):567-71. PubMed ID: 10605681
[TBL] [Abstract][Full Text] [Related]
8. [Positron emission tomography in the diagnosis and follow up of non-small cell lung cancer].
Vaylet F; Rivière F; Le Floch H; Bonnichon A; Mairovitz A; Staub E; Bonardel G; Margery J; Mantzarides M; Marotel C; Foehrenbach H
Rev Mal Respir; 2007 Oct; 24(8 Pt 2):6S35-9. PubMed ID: 18235392
[TBL] [Abstract][Full Text] [Related]
9. [Evaluation of fluorine-18-fluorodeoxyglucose whole body positron emission tomography imaging in the clinical diagnosis of lung cancer].
Demura Y; Mizuno S; Wakabayashi M; Totani Y; Okamura S; Ameshima S; Ishizaki T; Miyamori I; Ito H; Yonekura Y
Nihon Kokyuki Gakkai Zasshi; 2000 Sep; 38(9):676-81. PubMed ID: 11109804
[TBL] [Abstract][Full Text] [Related]
10. Correlation of Glut-1 glucose transporter expression with.
Higashi K; Ueda Y; Sakurai A; Wang XM; Xu L; Murakami M; Seki H; Oguchi M; Taki S; Nambu Y; Tonami H; Katsuda S; Yamamoto I
Eur J Nucl Med; 2000 Dec; 27(12):1778-85. PubMed ID: 11189940
[TBL] [Abstract][Full Text] [Related]
11. Non-small cell lung cancer: FDG PET for nodal staging in patients with stage I disease.
Farrell MA; McAdams HP; Herndon JE; Patz EF
Radiology; 2000 Jun; 215(3):886-90. PubMed ID: 10831716
[TBL] [Abstract][Full Text] [Related]
12. Prospective use of serial questionnaires to evaluate the therapeutic efficacy of 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) in suspected lung cancer.
Herder GJ; Van Tinteren H; Comans EF; Hoekstra OS; Teule GJ; Postmus PE; Joshi U; Smit EF
Thorax; 2003 Jan; 58(1):47-51. PubMed ID: 12511720
[TBL] [Abstract][Full Text] [Related]
13. PET in lung cancer.
Coleman RE
J Nucl Med; 1999 May; 40(5):814-20. PubMed ID: 10319756
[TBL] [Abstract][Full Text] [Related]
14. Preoperative mediastinal and hilar nodal staging with diffusion-weighted magnetic resonance imaging and fluorodeoxyglucose positron emission tomography/computed tomography in patients with non-small-cell lung cancer: which is better?
Wu LM; Xu JR; Gu HY; Hua J; Chen J; Zhang W; Haacke EM; Hu J
J Surg Res; 2012 Nov; 178(1):304-14. PubMed ID: 22541065
[TBL] [Abstract][Full Text] [Related]
15. Positron emission tomographic imaging with fluorodeoxyglucose isefficacious in evaluating malignant pulmonary disease.
Graeber GM; Gupta NC; Murray GF
J Thorac Cardiovasc Surg; 1999 Apr; 117(4):719-27. PubMed ID: 10096967
[TBL] [Abstract][Full Text] [Related]
16. 18-fluorodeoxyglucose positron emission tomography enhances computed tomography diagnosis of malignant intraductal papillary mucinous neoplasms of the pancreas.
Sperti C; Bissoli S; Pasquali C; Frison L; Liessi G; Chierichetti F; Pedrazzoli S
Ann Surg; 2007 Dec; 246(6):932-7; discussion 937-9. PubMed ID: 18043094
[TBL] [Abstract][Full Text] [Related]
17. Positron emission tomography in lung cancer.
Shon IH; O'doherty MJ; Maisey MN
Semin Nucl Med; 2002 Oct; 32(4):240-71. PubMed ID: 12524650
[TBL] [Abstract][Full Text] [Related]
18. [Current data and perspectives on positron emission tomography oncology-radiotherapy].
Lonneux M; Sibomana M; Pauwels S; Grégoire V
Cancer Radiother; 1999; 3(4):275-88. PubMed ID: 10486538
[TBL] [Abstract][Full Text] [Related]
19. [Diagnosis of early cancer with positron emission tomography].
Kubota K
Nihon Rinsho; 1996 May; 54(5):1263-7. PubMed ID: 8965348
[TBL] [Abstract][Full Text] [Related]
20. Increased (18)F-fluorodeoxyglucose uptake in benign, nonphysiologic lesions found on whole-body positron emission tomography/computed tomography (PET/CT): accumulated data from four years of experience with PET/CT.
Metser U; Even-Sapir E
Semin Nucl Med; 2007 May; 37(3):206-22. PubMed ID: 17418153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
